Buprenorphin Produkt Beschreibung

  • CAS-Nr.52485-79-7
  • Bezeichnung:Buprenorphin
  • Englisch Name:BUPRENORPHINE
  • Synonyma:Buprenorphin
  • CBNumber:CB0279103
  • Summenformel:C29H41NO4
  • Molgewicht:467.65
  • MOL-Datei:52485-79-7.mol
Buprenorphin physikalisch-chemischer Eigenschaften
  • Kennzeichnung gefährlicher :F,T
  • R-Sätze: :11-23/24/25-39/23/24/25
  • S-Sätze: :16-36/37-45-7
  • RIDADR  :UN1230 - class 3 - PG 2 - Methanol, solution
  • WGK Germany  :1
  • Toxizität :LD50 oral in mouse: 260mg/kg

BUPRENORPHINE Chemische Eigenschaften,Einsatz,Produktion Methoden

  • Chemische Eigenschaften White Solid
  • Verwenden Controllled substance (narcotic). Analgesic that demonstrates narcotic agonist-antagonist properties.
  • Definition ChEBI: A morphinane alkaloid that is 7,8-dihydromorphine 6-O-methyl ether in which positions 6 and 14 are joined by a -CH2CH2- bridge, one of the hydrogens of the N-methyl group is su stituted by cyclopropyl, and a hydrogen at position 7 is substituted by a 2-hydroxy-3,3-dimethylbutan-2-yl group.
  • Trademarks Buprenex (Reckitt Benckiser); Subutex (Reckitt Benckiser);Buprex;Buprx;Finibron;Prefin;Temagesic.
  • Weltgesundheitsorganisation (WHO) Buprenorphine, an opioid analgesic with both morphine agonist and antagonist activity, was introduced in 1978. It was originally considered to possess low dependence potential. However, it has latterly been identified as causing a socially significant abuse problem in several countries which have consequently subjected it to control in 1989 under Schedule III of the 1971 Convention of Psychotropic Substances. (Reference: (UNCPS3) United Nations Convention on Psychotropic Substances (III), , , 1971)
  • Biologische Funktion Buprenorphine (Temgesic) is a mixed agonist–antagonist and a derivative of the naturally occurring opioid thebaine. Buprenorphine is highly lipophilic and is 25 to 50 times more potent than morphine as an analgesic. The sedation and respiratory depression it causes are more intense and longer lasting than those produced by morphine. Its respiratory depressant effects are not readily reversed by naloxone. It binds to the -receptor with high affinity and only slowly dissociates from the receptor, which may explain the lack of naloxone reversal of respiratory depression.
    Buprenorphine has more agonist than antagonist effects and is often considered a partial agonist rather than a mixed agonist–antagonist, although it precipitates withdrawal in opioid-dependent patients. Its pharmacological effects are similar to those produced by both morphine and pentazocine. Indications for its use are similar to those of pentazocine, that is, for moderate to severe pain. Sublingual preparations are available, but have a slow onset and erratic absorption. The abuse potential of buprenorphine is low.While high doses of the drug are perceived by addicts as being morphinelike, it does reduce the craving for morphine and for the stimulant cocaine. Thus, buprenorphine is a potential new therapy for the treatment of addiction to both classes of drugs.
    Drug interactions and contraindications are similar to those described for pentazocine and morphine.
  • Allgemeine Beschreibung Buprenorphine is a semisynthetic, highly lipophilic opiate derivedfrom thebaine. Pharmacologically, it is classified as amixed μ-agonist/antagonist (a partial agonist) and a weak κ-antagonist. It has a high affinity for the μ-receptors(1,000 times greater than morphine) and a slow dissociationrate leading to its long duration of action (6–8 hours). Atrecommended doses, it acts as an agonist at the μ-receptorwith approximately 0.3 mg IV equianalgesic to 10 mg of IVmorphine. One study in humans found that buprenorphine displaysa ceiling effect to the respiratory depression, but not theanalgesic effect over a dose range of 0.05 to 0.6 mg.In practice,this makes buprenorphine a safer opiate (when usedalone) than pure μ-agonists. Relatively few deaths frombuprenorphine overdose (when used alone) have been reported.113 The tight binding of the drug to the receptor also hasled to mixed reports on the effectiveness of using naloxone toreverse the respiratory depression. In animal studies, normaldoses of the pure antagonist naloxone were unable to removebuprenorphine from the receptor site and precipitate withdrawal.In a human study designed to precipitate withdrawalfrom buprenorphine, a naloxone dose (mean=35 mg) 100times the dose usually needed to precipitate withdrawal inmethadone-dependent subjects was used. For comparison, approximately0.3 mg, 4 mg, 4 mg, and 10 mg of naloxonewould be required to precipitate withdrawal from heroin, butorphanol,nalbuphine, or pentazocine respectively.
  • Kontakt-Allergie This semisynthetic opioid analgesic drug is derived fromwith transdermal systems (TDS). In case of localized or generalized allergic contact dermatitis due to buprenorphine in TDS, TDS containing fentanyl can be safely used thebaine. It can be used parenterally, orally, and topically
BUPRENORPHINE Upstream-Materialien And Downstream Produkte
Downstream Produkte
Buprenorphin Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
52485-79-7, BUPRENORPHINE Verwandte Suche:
  • 6,14-ethenomorphinan-7-methanol,17-(cyclopropylmethyl)-alpha-(1,1-dimethylethy
  • l)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-alpha-methyl-,(5-alpha,7-alpha
  • rx6029m
  • [5a,7a(S)]-17-(Cyclopropylmethyl)-a-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-a-methyl-6,14-ethenomorphinan-7-methanol Hydrochloride
  • Buprenex
  • CL-112302
  • Lepetan
  • NIH-8805
  • Subutex
  • Temgesi
  • UM-952
  • 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-.alpha.-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-.alpha.-methyl-, (.alpha.S,5.alpha.,7.alpha.)-
  • 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-α-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-α-methyl-, (αS,5α,7α)-
  • 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-α-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-α-methyl-, [5α,7α(S)]-
  • Temgesic
  • Buprenorphine (base and/or unspecified salts)
  • [5a,7a(S)]-17-(Cyclopropylmethyl)-α-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-α-methyl-6,14-ethenomorphinan-7-methanol Hydrochloride
  • BuprenorphineBase(Narcotic)C29H41No4,Edmf
  • Buprenorphine Base (Narcotic)
  • Buprenorphine solution
  • (αS)-17-(Cyclopropylmethyl)-α-(1,1-dimethylethyl)-4,5α-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-α-methyl-6,14-ethenomorphinan-7α-methanol
  • Buprenorfin
  • Methanol (test Buprenorphine,100ug/mL)
  • (4R,4aS,6R,7R,7aR,12bS)-3-(cyclopropylmethyl)-6-((S)-2-hydroxy-3,3-dimethylbutan-2-yl)-7-methoxy-1,2,3,4,5,6,7,7a-octahydro-4a,7-ethano-4,12-methanobenzofuro[3,2-e]isoquinolin-9-ol
  • Buprenorphine (1.0mg/ml in Acetonitrile)
  • Buprenorphine EP Impurity A
  • Buprenorphine EP Impurity B
  • Buprenorphine EP Impurity C
  • Buprenorphine EP Impurity D
  • Buprenorphine EP Impurity E
  • Buprenorphine EP Impurity F
  • Buprenorphine EP Impurity G
  • Buprenorphine EP Impurity H
  • Buprenorphine EP Impurity I
  • Buprenorphine EP Impurity J
  • 52485-79-7
  • 652485-79-7
  • C29H41NO4
  • C29H42ClNO4
  • Intermediates & Fine Chemicals
  • Pharmaceuticals